全文获取类型
收费全文 | 688篇 |
免费 | 37篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 14篇 |
妇产科学 | 20篇 |
基础医学 | 103篇 |
口腔科学 | 25篇 |
临床医学 | 86篇 |
内科学 | 163篇 |
皮肤病学 | 14篇 |
神经病学 | 35篇 |
特种医学 | 16篇 |
外科学 | 50篇 |
综合类 | 5篇 |
预防医学 | 31篇 |
眼科学 | 38篇 |
药学 | 86篇 |
中国医学 | 4篇 |
肿瘤学 | 35篇 |
出版年
2023年 | 12篇 |
2022年 | 12篇 |
2021年 | 42篇 |
2020年 | 32篇 |
2019年 | 35篇 |
2018年 | 35篇 |
2017年 | 24篇 |
2016年 | 31篇 |
2015年 | 33篇 |
2014年 | 54篇 |
2013年 | 47篇 |
2012年 | 53篇 |
2011年 | 81篇 |
2010年 | 22篇 |
2009年 | 27篇 |
2008年 | 66篇 |
2007年 | 45篇 |
2006年 | 27篇 |
2005年 | 21篇 |
2004年 | 13篇 |
2003年 | 7篇 |
2002年 | 5篇 |
2001年 | 1篇 |
1999年 | 1篇 |
1997年 | 1篇 |
排序方式: 共有727条查询结果,搜索用时 211 毫秒
1.
Sreenivasan Prem K. K.V.V Prasad Sharda Shweta Pothamsetty Yogitha 《Clinical oral investigations》2021,25(10):5785-5793
Clinical Oral Investigations - This study compared the effects of oral hygiene with a toothpaste formulated with zinc (test) to a fluoride dentifrice (control) for effects on oral polymorphonuclear... 相似文献
2.
3.
4.
5.
6.
PurposeIn 2011, we introduced an innovative parallel curriculum at Baylor College of Medicine, formerly called the Genetics Track Curriculum and now called the Genetics and Genomics Pathway, aimed at providing an opportunity for an enriched educational experience throughout medical school. In this report, we describe our 10-year experience with the program and highlight growth in enrollment as well as academic achievements of graduating students.MethodsWe reviewed the data of students enrolled in this pathway, including retention, satisfaction, student-driven curriculum changes, scholarly outcomes, and career outcomes.ResultsFrom September 2011 to June 2021, 121 students were enrolled in the Genetics and Genomics Pathway program. In total, 64 students (64/121 = 53%) left the program before graduating (the majority, after their first year). Of the 57 remaining students, 29 graduated (29/57, approximately 51%), and 4 of the 29 students (4/29 = 14%) matched into a genetics training program.ConclusionThis novel program serves as a mechanism for garnering increased interest and competence in medical genetics. The longitudinal nature of the program fosters enthusiasm for genetics and provides ample opportunity to develop valuable research skills. Given the ongoing shortage of providers in this field, such programs are vital to increase the size of the workforce and broaden the knowledge of providers in diverse fields. 相似文献
7.
Dipak R. Patel Shweta Urva Stephen Ho Cody J. Buckman Yanfei Ma Jean Lim Sean E. Sissons Mary S. Zuniga Diane Philips Karen Cox Daniel J. Dairaghi 《CTS Clinical and Translational Science》2021,14(3):1037
AbstractLY2775240 is a highly selective, potent and orally‐administered inhibitor of phosphodiesterase 4 (PDE4), and is being investigated as a treatment option for inflammatory disorders, such as psoriasis. LY2775240 was investigated in rodent and rhesus monkey nonclinical models. Treatment with LY2775240 led to significant reductions in TNFα production, a marker of PDE4 engagement upon immune activation, in both nonclinical models. In the first part of a 2‐part first‐in‐human randomized study, a wide dose range of LY2775240 was safely evaluated and found to be well‐tolerated with common adverse events (AEs) of nausea, diarrhea, and headache. No serious AEs were reported. The pharmacokinetic profile of LY2775240 was well‐characterized, with a half‐life that can support once‐a‐day dosing. An ex vivo pharmacodynamic (PD) assay demonstrated dose‐dependent PDE4 target engagement as assessed by reduction in TNFα production. A 20 mg dose of LY2775240 led to near‐maximal TNFα inhibition in this PD assay in the first part of the study and was selected for comparison with the clinical dose of apremilast (30 mg) in the crossover, second part of this study. The 20 mg dose of LY2775240 demonstrated sustained maximal (50%–80%) inhibition of TNFα over all timepoints over the 24‐h duration. The comparator apremilast achieved peak inhibition of ~ 50% at only 4 h postdose with a return to about 10% inhibition within 12 h of dosing. In summary, the nonclinical data and safety, tolerability, and PK/PD data in healthy subjects supports further investigation of LY2775240 in inflammatory indications. Study Highlights
- WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
- WHAT QUESTION DID THIS STUDY ADDRESS?
- WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
- HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?
8.
Rajib Dasgupta Shweta Sharma Nisha Sharma K. Banerjee E.G.P. Haran J.P. Muliyel Subhash Salunke Muneer Ahmad Masoodi Pradeep Haldar Sunil Bahl Pankaj Bhatnagar Sudhir Joshi Narendra K. Arora 《Vaccine》2019,37(17):2394-2400
In accordance with the end game strategies for polio eradication a synchronized switch plan from tOPV to bOPV was implemented globally in 2016. The National Committee for Polio Eradication (NCCPE) validated the switch activities in India. An expert group of 104 academics conducted field visits in 25 states and 2 Union territories for independent verification (after an initial round of verification by the National Polio Surveillance Project [NPSP]). The objectives were to validate withdrawal and disposal of tOPV by screening cold chain points in public and private sector health facilities in both rural and urban areas; additionally, availability of bOPV and IPV was also documented. 34 filled tOPV and 5 empty vials were detected inside cold chain equipment and 17 outside. The disposal mechanism was found to be reasonably adequate. The key strategies -- ‘throttling’ of vaccine supplies well ahead of the switch date while preventing stock outs at various immunization points, simultaneously working with the regulators to delicense the tOPV on the switch date and helping manufacturers to calibrate vaccine production according to national timelines, and strong and persistent advocacy with professional associations to align with national bOPV and IPV policy facilitated successful accomplishment of the switch process. Effective implementation of the switch strategy in India also bears testimony to the resilience of the health system operating under diverse and heterogeneous governance. 相似文献
9.
10.